Background/Aims Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.
Methods We analyzed data from CHB patients for whom initiated NA treatment from 30 centers. We balanced patient characteristics with and without metabolic disease (diabetes, obesity, dyslipidemia, and hypertension) via propensity-score matching (PSM) to evaluate adverse outcomes.
Results The study included 4,500 patients. PSM yielded 909 pairs of patients with balanced characteristics. When stratified by the number of metabolic diseases, only patients with ≥2 metabolic diseases had an increased cumulative incidence of cirrhosis and overall death. However, when stratified by the presence of diabetes (regardless of the presence or number of other metabolic diseases), patients with diabetes (versus those without) had a significantly higher cumulative incidence of all outcomes: cirrhosis (P=0.009), hepatocellular carcinoma (HCC, P=0.023), and overall, liver-related, and non-liver-related death (P<0.001, P=0.026 and P<0.001, respectively). Having ≥2 metabolic diseases was associated with cirrhosis, overall death, and non-liver-related death but not HCC or liver-related death, while diabetes was significantly associated with a higher risk of all outcomes: cirrhosis (hazard ratio [HR]=3.75, P=0.004), HCC (HR=2.02, P=0.020), and overall, liver-related, and non-liver-related death (HR=2.53, P<0.001; HR=2.65, P=0.016; HR=2.38, P<0.001).
Conclusions Having two or more metabolic diseases was associated with a higher risk of cirrhosis, overall death, and non-liver-related death, but having diabetes as a single metabolic disease was significantly associated with all adverse outcomes including cirrhosis, HCC, and overall, liver-related, and non-liver-related death.
Citations
Citations to this article as recorded by
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2026; 83(5): 1273. CrossRef
Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection Talal K Bhatti, Joseph K Lim World Journal of Gastroenterology.2026;[Epub] CrossRef
Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor Aoyi Li, Yan Han, Guanglin Xiao, Zhiling Deng, Chaojing Wen, Ke Qiu, Taiyu He, Hong Ren Journal of Clinical Medicine.2026; 15(5): 1826. CrossRef
Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase Jian Wang, Zhiyi Zhang, Li Zhu, Tao Fan, Ye Xiong, Shaoqiu Zhang, Chao Jiang, Shengxia Yin, Xin Tong, Juan Xia, Xiaomin Yan, Renling Yao, Yu Shi, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus Shang-Chin Huang, Jia-Horng Kao Biomedical Journal.2026; 49(3): 100969. CrossRef
Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng Annals of Medicine.2026;[Epub] CrossRef
Diagnosing and defining MASLD in people living with chronic hepatitis B Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews Communications Medicine.2026;[Epub] CrossRef
The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe? Shang-Chin Huang, Tai-Chung Tseng Gut and Liver.2026; 20(3): 350. CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang Emerging Microbes & Infections.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Multifunctional Metal Composite Hydrogels for Diabetic Wound Therapy Shengnan Zhang, Hui Gao, Kevin H. Mayo, Jingang Mo, Le Deng Gels.2025; 11(12): 960. CrossRef
As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, and the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.
Citations
Citations to this article as recorded by
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial” Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Dynamics and Sensitivity of the Lifecycle of Hepatitis B Virus Dmitry Grebennikov, Igor Sazonov, Rostislav Savinkov, Matvey Zakharov, Mark Sorokin, Yakov Mokin, Andreas Meyerhans, Gennady Bocharov Pathogens.2026; 15(2): 172. CrossRef
ZNF638 represses the transcription of HBV closed circular DNA involving HUSH complex-mediated histone modifications of epigenetic silencing Sifan Meng, Jiaqian Li, Yunlong Fang, Binwei Duan, Jing Wang, Yang Si, Feng Li, Qiong Wu, Shan Cheng, Wei Ding Cell Communication and Signaling.2026;[Epub] CrossRef
Response to letters to editor "Next-Step Paradigms for Hepatitis B Functional Cure: Insights from the Anchor Combination Therapy Trial" and “Critical Appraisal of the Anchor RCT on Entecavir, Peginterferon Alfa-2b, and GM-CSF Combination Therapy” Di Wu, Da Huang, Weiming Yan, Qin Ning Hepatology International.2026;[Epub] CrossRef
Response to letter to editor—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon Jianxia Dong, Sujun Zheng, Xinyue Chen Hepatology International.2026;[Epub] CrossRef
Mechanisms and management of pegylated interferon-α toxicity in chronic hepatitis B Liya Zhu, Fei Peng, Dingfang Pi, Jinzhi Lu Frontiers in Immunology.2026;[Epub] CrossRef
Long-term antiviral therapy sustains HBsAg decline, increases HBV RNA negativity and enhances the proportion of patients achieving functional cure in chronic hepatitis B Ruihan Gao, Shuting Liu, Shiyu Zhang, Xin Zhou, Bin Zhu, Baoju Wang Annals of Hepatology.2026; 31(2): 102212. CrossRef
Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks Kui Wang, Ruchen Zhou Clinical and Molecular Hepatology.2026; 32(2): e211. CrossRef
A Comparative Study of Entecavir and Tenofovir Alafenamide on Quantitative HBsAg Reduction in Patients With CHB Jungnam Lee, Young‐Joo Jin Journal of Medical Virology.2026;[Epub] CrossRef
Hepatitis B in Children: A Review of Current Knowledge and Future Directions Paola Carolina Espin Diaz, Swati Antala Current Treatment Options in Pediatrics.2026;[Epub] CrossRef
Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications Wen Kang, Yu-Shen Liu, Tian-Ping Wang, Shu-Ming Zhang, Yu Li, Ye Zhang iLIVER.2026; 5(2): 100235. CrossRef
Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controll Qiran Zhang, Feng Sun, Shulan Sui, Jianmei Lin, Chuncheng Wu, Jing Yuan, Yingli He, Jia Shang, Tao Han, Ying Zhu, Zuxiong Huang, Chen Chen, Chao Qiu, Xing Wang, Jiming Zhang, Yao Xie, Wenhong Zhang Advances in Therapy.2026;[Epub] CrossRef
Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection Yiwen Shu, Sumeng Li, Yanqin Du, Xin Zheng Frontiers in Immunology.2025;[Epub] CrossRef
Quantitatively Evaluate the Improvement of Functional Cure for the Quality of Life of Chronic Hepatitis B Cases: Evidence from a Cross-Sectional Study in China Sihui Zhang, Zhiliang Gao, Hui Li, Yi Kang, Lei Fu, Xuebing Chen, Xiaoyuan Xu, Xinyue Chen, Hui Zhuang, Hui Zheng, Fuqiang Cui Healthcare.2025; 13(20): 2590. CrossRef
Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study Yong-Hong Wang, Ya-Chao Tao, Meng-Lan Wang, Cheng-Run Song, Jiang-Nan Peng, En-Qiang Chen Journal of Virus Eradication.2025; 11(4): 100617. CrossRef
An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection Ze-Ao Huang, Yang Yang, Shuo Yang, Guang-Shen Ji, Rui Fu, Zhi-Kang Tian, Yu-Cheng Wu, Geng-Shen Song Nature Communications.2025;[Epub] CrossRef
A Study on Serum Protein Tracking in Patients with Low Levels of HBsAg Undergoing Treatment for Chronic Hepatitis B with a Combination of Tenofovir Disoproxil Fumarate and Pegylated Interferon Yimin Chen, Min Deng, Mingkai Tong, Peixia Lin, Hua Xuan, Dahai Wei Hepatitis Monthly.2025;[Epub] CrossRef
Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study Jianxia Dong, Shan Ren, Jing Zhao, Pengxuan Wu, Haitian Yu, Yao Xie, Junliang Fu, Xiaorong Mao, Zhiliang Gao, Bingliang Lin, Qingfa Ruan, Yongfang Jiang, Xiulan Xue, Yueyong Zhu, Haidong Zhao, Haifang Cao, Xinyue Chen, Sujun Zheng Virology Journal.2025;[Epub] CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao Hepatoma Research.2025;[Epub] CrossRef
The current requirement for biomarkers to detect hepatitis B virus (HBV) infection is polarized. One is a fully-automated and highly sensitive measurement system; the other is a simple system for point-of-care testing (POCT) in resource-limited areas. Hepatitis B core-related antigen (HBcrAg) reflects intrahepatic covalently closed circular DNA and serum HBV DNA. Even in patients with undetectable serum HBV DNA or HBsAg loss, HBcrAg may remain detectable. Decreased HBcrAg levels are associated with reduction of the occurrence of hepatocellular carcinoma (HCC) in chronic hepatitis B. Recently, a fully-automated, novel high-sensitivity HBcrAg assay (iTACT-HBcrAg, cut-off value: 2.1 logIU/mL) has been developed. This attractive assay has been released in Japan very recently. iTACT-HBcrAg can be useful for monitoring HBV reactivation and prediction of HCC occurrence, as an alternative to HBV DNA. Moreover, monitoring HBcrAg may be suitable for determining the therapeutic effectiveness of approved drugs and novel drugs under development. Presently, international guidelines recommend anti-HBV prophylaxis for pregnant women with high viral loads to prevent mother-to-child transmission of HBV. However, >95% of HBV-infected individuals live in countries where HBV DNA quantification is not available. Worldwide elimination of HBV needs the scaling-up of examination and medication services in resource-limited areas. Based on this situation, a rapid and easy HBcrAg assay as a POCT is valuable. This review provides the latest information regarding the clinical use of a new surrogate marker, HBcrAg, in HBV management, based on iTACT-HBcrAg or POCT, and introduces novel agents targeting HBV RNA/protein.
Citations
Citations to this article as recorded by
Similar hepatic outcome by SGLT2i vs. DPP4i for at-risk cohort with CHB & T2DM: A nationwide target trial emulation study Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon Annals of Hepatology.2026; 31(1): 102175. CrossRef
Strategic analysis of hepatitis B virus serological profile and the diagnostic utility of HBcrAg across Osun and Plateau State, Nigeria Priscilla Abechi, Uwem E. George, Olamide Y. Aborisade, Arthur O. Oragwa, Oluwatomisin P. Osijonwo, Oluremi I. Ajayi, Olusola A. Ogunsanya, Christian Happi, Onikepe A. Folarin Journal of Immunoassay and Immunochemistry.2026; 47(2): 129. CrossRef
High Intrahepatic cccDNA in Resolved HBV Infection: Insights From Living Donor Liver Transplantation With Anti‐HBc‐Positive Grafts Sung Kwan Bae, Nobuhisa Akamatsu, Akihiko Ichida, Yujiro Nishioka, Yoshinori Inagaki, Nozomi Miyake, Takeshi Takamoto, Yoshikuni Kawaguchi, Sumihito Tamura, Junichi Arita, Junichi Kaneko, Motoyuki Otsuka, Yasuhito Tanaka, Hiroshi Yotsuyanagi, Kyoji Moriya Journal of Gastroenterology and Hepatology.2026; 41(4): 1335. CrossRef
Analysis of HBV Genome Integration in Patients With HBV‐Previously Infected NBNC‐HCC Tomoya Saito, Rigel Suzuki, Akhinur Rahman, Kento Mori, Samiul Alam Rajib, Nobuhiro Kobayashi, Yoichi Yamamoto, Sharmin Nahar Sithi, Takaya Ichikawa, Tatsuya Orimo, Tatsuhiko Kakisaka, Lihan Liang, Naganori Nao, Saori Suzuki, Tomokazu Tamura, Yorifumi Sat Hepatology Research.2026;[Epub] CrossRef
Clinical utility of hepatitis B core-related antigen in chronic hepatitis B infection: diagnostic, prognostic, and therapeutic implications Bukhari Isah Shuaib, Usman Linda Itunu, Aminat Daud Egyptian Liver Journal.2026;[Epub] CrossRef
Host Factors DDB2 and DNA Polymerase Delta Are Linked to cccDNA Persistence in Hepatitis B Virus and Occult Hepatitis B Virus‐Related Hepatocellular Carcinoma Kanyakorn Singsung, Athaya Vorasittha, Pisit Tangkijvanich, Yasuhito Tanaka, Natthaya Chuaypen, Pongserath Sirichindakul Journal of Viral Hepatitis.2026;[Epub] CrossRef
Greater Reductions in Hepatitis B Core-Related Antigen Associated with Switching from Entecavir to Tenofovir Alafenamide Compared with Continued Entecavir Therapy: A Retrospective Observational Study Masanori Fukushima, Satoshi Miuma, Yasuhiko Nakao, Ryu Sasaki, Masafumi Haraguchi, Hisamitsu Miyaaki Journal of Clinical Medicine.2026; 15(11): 4021. CrossRef
Rapid test for hepatitis B core-related antigen to identify people living with hepatitis B having high viral load in Cameroon Richard Njouom, Alassane Ndiaye, Abdou Fatawou Modiyinji, Frederic Lissock, Jeanne Perpétue Vincent, Masaya Baba, Naoki Yamamoto, Atsushi Kaneko, Katsumi Aoyagi, Naofumi Hashimoto, Mari Nagai, Masato Ichikawa, Tetsuo Miura, Wataru Sugiura, Yasuhito Tanaka Virology.2025; 602: 110316. CrossRef
Achieving chronic hepatitis B functional cure: Factors and potential mechanisms Jiarui Zheng, Zilong Wang, Linxiang Huang, Zixuan Qiu, Yandi Xie, Suzhen Jiang, Bo Feng Virus Research.2025; 351: 199507. CrossRef
Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B Takuya Matsubara, Satoru Hagiwara, Naoshi Nishida, Naoya Omaru, Akihiro Yoshida, Tomoki Yamamoto, Yoriaki Komeda, Mamoru Takenaka, Masatoshi Kudo Scientific Reports.2025;[Epub] CrossRef
Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients Qiyao Wei, Jing Zhao BMC Gastroenterology.2025;[Epub] CrossRef
Antiviral Therapy-Induced Changes in Long Non-Coding RNA Expression Profiles in Umbilical Cord Blood and Placental Tissues of Hepatitis B Virus-Infected Pregnant Women Cuimin Wang, Yuting Huang, Lanfeng Li, Xizhen Huang, Yin Huang, Xiang Fang, Yu Long International Journal of Women's Health.2025; Volume 17: 835. CrossRef
Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC Beom Kyung Kim Alimentary Pharmacology & Therapeutics.2025; 61(10): 1717. CrossRef
Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC—Authors' Reply Subin Heo, Won‐Mook Choi Alimentary Pharmacology & Therapeutics.2025; 61(10): 1719. CrossRef
HBcrAg Dynamic Change During Treatment Predicts HBsAg Loss in Pediatric Patients With Chronic Hepatitis B Ling Ye, Wenxian Ouyang, Yingping Gu, Zhenzhen Yao, Xin Lai, Sisi Li, Meng Yang, Songxu Peng Journal of Medical Virology.2025;[Epub] CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C Beom Kyung Kim Journal of Gastroenterology and Hepatology.2025; 40(8): 1855. CrossRef
Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K Journal of Gastroenterology and Hepatology.2025; 40(6): 1595. CrossRef
Hepatitis B core-related antigen as a predictive biomarker for recurrence in primary hepatocellular carcinoma: A meta-analysis Ling-Bo Liang, Hai-Jun Zhang, Feng Liu, Qiao-Li Su World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
Construction and validation of a nomogram prediction model for antiviral efficacy based on clinical characteristics and intestinal microflora distribution in patients with chronic hepatitis B Hongjie Wu, Mingqiang Yue, Tianbao Wang, Xiaoxia Wei, Yanping Wang, Changyun Si Frontiers in Medicine.2025;[Epub] CrossRef
Clinical outcomes after HBsAg clearance in chronic hepatitis B patients treated with Peg-IFN α: A study with an 11- to 173-month follow-up Wen Deng, Hongxiao Hao, Ziyu Zhang, Xinxin Li, Weihua Cao, Yaqin Zhang, Shiyu Wang, Zixuan Gao, Linmei Yao, Shuojie Wang, Xin Wei, Wei Yi, Linqing Zhao, Yao Xie, Minghui Li Virologica Sinica.2025; 40(4): 579. CrossRef
Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study Yong-Hong Wang, Ya-Chao Tao, Meng-Lan Wang, Cheng-Run Song, Jiang-Nan Peng, En-Qiang Chen Journal of Virus Eradication.2025; 11(4): 100617. CrossRef
An RNA‐degrading enzyme emerges as a biomarker in a study of human hepatitis virus B Takehisa Watanabe, Katsuya Nagaoka Hepatology Research.2024; 54(3): 220. CrossRef
Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy Ritsuzo Kozuka, Masaru Enomoto, Yoshimi Yukawa‐Muto, Naoshi Odagiri, Kohei Kotani, Hiroyuki Motoyama, Etsushi Kawamura, Atsushi Hagihara, Hideki Fujii, Sawako Uchida‐Kobayashi, Norifumi Kawada Hepatology Research.2024; 54(7): 615. CrossRef
Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B Tomohiro Nishikawa, Masahiro Matsui, Saori Onishi, Kosuke Ushiro, Akira Asai, Soo-Ki Kim, Hiroki Nishikawa International Journal of Molecular Sciences.2024; 25(4): 2245. CrossRef
Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment Lisa Sandmann, Birgit Bremer, Valerie Ohlendorf, Jerzy Jaroszewicz, Heiner Wedemeyer, Markus Cornberg, Benjamin Maasoumy Viruses.2024; 16(2): 255. CrossRef
Identification of dihydroquinolizinone derivatives with nitrogen heterocycle moieties as new anti-HBV agents Huijuan Song, Shangze Yang, Shuo Wu, Xiaoyu Qin, Ya Wang, Xican Ma, Jiaqi Gong, Meng Wei, Apeng Wang, Mengyuan Wang, Kun Lan, Juan Guo, Mingliang Liu, Xingjuan Chen, Yuhuan Li, Kai Lv European Journal of Medicinal Chemistry.2024; 268: 116280. CrossRef
Quantitative Measurement of Serum HBcrAg Can Be Used to Assess the Feasibility of Safe Discontinuation of Antiviral Therapy for Chronic Hepatitis B Yong-Hong Wang, Hong Tang, En-Qiang Chen Viruses.2024; 16(4): 529. CrossRef
Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu Clinical and Molecular Hepatology.2024; 30(2): 293. CrossRef
Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu Clinical and Molecular Hepatology.2024; 30(2): 276. CrossRef
Current perspectives of viral hepatitis Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou, World Journal of Gastroenterology.2024; 30(18): 2402. CrossRef
Two Concepts of Hepatitis B Core-Related Antigen Assay: A Highly Sensitive and Rapid Assay or an Effective Tool for Widespread Screening Takako Inoue, Shintaro Yagi, Yasuhito Tanaka Viruses.2024; 16(6): 848. CrossRef
Novel biomarkers for chronic hepatitis B management Tai-Chung Tseng Clinical Liver Disease.2024;[Epub] CrossRef
Role of circular RNAs in preeclampsia (Review) Hengxue Jiang, Tao Meng, Ziwei Li Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus Philippa C. Matthews, Ponsiano Ocama, Su Wang, Manal El-Sayed, Anna Turkova, Deborah Ford, Judith Torimiro, Ana Cristina Garcia Ferreira, Angélica Espinosa Miranda, Fernando Pio De La Hoz Restrepo, Emmanuel Seremba, Robinson Mbu, Calvin Q. Pan, Homie Raza JHEP Reports.2023; 5(8): 100777. CrossRef
Hepatitis B virus (HBV) cannot be eliminated completely from infected hepatocytes because of the presence of intrahepatic covalently closed circular DNA (cccDNA). As chronic hepatitis B (CHB) can progress to cirrhosis and hepatocellular carcinoma (HCC), it is important to manage CHB to prevent HCC development in high-risk patients with high viral replicative activity or advanced fibrosis. Serum biomarkers are noninvasive and valuable for the management of CHB. Hepatitis B core-related antigen (HBcrAg) correlates with serum HBV DNA and intrahepatic cccDNA. In CHB patients with undetectable serum HBV DNA or loss of HBsAg, HBcrAg still can be detected and the decrease in HBcrAg levels is significantly associated with hopeful outcomes. Therefore, HBcrAg can predict HCC occurrence or recurrence. Measurement of the Mac-2 binding protein glycosylation isomer (M2BPGi) has been introduced for the evaluation of liver fibrosis. Because elevated M2BPGi in CHB is related to liver fibrosis and the prediction of HCC development, monitoring its progression is essential. Because alpha fetoprotein (AFP) has insufficient sensitivity and specificity for early-stage HCC, a combination of AFP plus protein induced by vitamin K absence factor II, or AFP plus Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein might improve the diagnosis of HCC development. Additionally, Dickkopf-1 and circulating immunoglobulin G antibodies are the novel markers to diagnose HCC or assess HCC prognosis. This review provides an overview of novel HBV biomarkers used for the management of intrahepatic viral replicative activity, liver fibrosis, and HCC development.
Citations
Citations to this article as recorded by
Electrochemical biosensors for MMP-9 in hepatitis B liver inflammation Khalid Saad Alharbi Clinica Chimica Acta.2026; 580: 120754. CrossRef
Nucleos(t)ide analogue treatment in hepatitis B: to stop or not to stop? Margarita Papatheodoridi, George Papatheodoridis Expert Review of Anti-infective Therapy.2026; 24(1): 113. CrossRef
Development of a hypersensitive digital ELISA system for hepatitis B core antigen Yuki Nakaya, Takema Hasegawa, Yuji Hoshi, Daichi Onomura, Tomoko Yamagata, Hiroaki Okamoto, Kazumoto Murata, Megumi Kato Analytical and Bioanalytical Chemistry.2026; 418(7): 2125. CrossRef
Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity Weili Kong, Jiali Zhang, Yingying Song, Jingjing Song, Yuebo Xu, Xinmu Xu, Haoyu Ma, Li Chen, Cong Zeng, Ryan A. Langlois Journal of Virology.2026;[Epub] CrossRef
Emerging roles of hepatitis B core-related antigen and HBV RNA as non-invasive biomarkers in chronic hepatitis B management Yan Mardian, Yusra, Merci Monica Pasaribu, Nuri Dyah Indrasari, Wahyu Aristyaning Putri Egyptian Liver Journal.2026;[Epub] CrossRef
Clinical utility of hepatitis B core-related antigen in chronic hepatitis B infection: diagnostic, prognostic, and therapeutic implications Bukhari Isah Shuaib, Usman Linda Itunu, Aminat Daud Egyptian Liver Journal.2026;[Epub] CrossRef
Overall Survival of Young Patients with Hepatocellular Carcinoma in Barcelona Clinic Liver Cancer Stage B in a Retrospective Study Based on a Multicenter Cohort Koji Fujita, Kyoko Oura, Asahiro Morishita, Takashi Himoto, Hideki Kobara Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Favourable Prognosis of Patients With Untreated HBeAg‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL Jian Wang, Zhiyi Zhang, Shengxia Yin, Shaoqiu Zhang, Li Zhu, Yifan Pan, Tao Fan, Fei Cao, Ye Xiong, Chao Jiang, Guiyang Wang, Yue Yang, Bei Jia, Jiacheng Liu, Juan Xia, Xiaomin Yan, Jie Li, Chuanwu Zhu, Xingxiang Liu, Yuxin Chen, Chao Wu, Rui Huang Alimentary Pharmacology & Therapeutics.2025; 61(3): 472. CrossRef
Growing evidence on the highly sensitive iTACT assay of hepatitis B core-related antigen for predicting hepatitis B virus reactivation Taiki Okumura, Takeji Umemura Journal of Gastroenterology.2025; 60(1): 129. CrossRef
Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure Yue Qiu, Qiao Tang, Xiao-Qing Liu, Yun-Ling Xue, Yi Zeng, Peng Hu World Journal of Hepatology.2025;[Epub] CrossRef
Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib Takeshi Terashima, Hidenori Kido, Noboru Takata, Tomoyuki Hayashi, Akihiro Seki, Hidetoshi Nakagawa, Kouki Nio, Tadashi Toyama, Noriho Iida, Shinya Yamada, Tetsuro Shimakami, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Eishiro Mizukoshi, Taro Yamash Cancers.2025; 17(2): 278. CrossRef
A cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion Chongwei Xie, Bing Zhou, Da Yao, Xin Wang, Lihong Zhong, Chuanghua Qiu, Junfang Zhang Virus Research.2025; 353: 199531. CrossRef
Accurate quantification of cell-free Ceruloplasmin mRNA as a biomarker for early detection of hepatocellular carcinoma Minh Ngo, Trang Dao, Trang Hoang, Ung Nguyen, Jakob Stenman, Huy Duong, Tho Ho Scientific Reports.2025;[Epub] CrossRef
A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B Sarafa A. Iyaniwura, Tyler Cassidy, Ruy M. Ribeiro, Alan S. Perelson, Amber M. Smith PLOS Computational Biology.2025; 21(5): e1012322. CrossRef
Plasma proteomic analysis reveals altered protein abundances in HIV/HBV co-infection individuals with HCC and with liver cirrhosis Yongxi Zhang, Ping Xu, Xingxia Yu, Ke Zhuang, Xien Gui, Rongrong Yang Scientific Reports.2025;[Epub] CrossRef
Hepatitis B core-related antigen as a predictive biomarker for recurrence in primary hepatocellular carcinoma: A meta-analysis Ling-Bo Liang, Hai-Jun Zhang, Feng Liu, Qiao-Li Su World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
Nouveaux outils et limites du diagnostic virologique des infections par le virus de l’hépatite B en 2025 Sarah Maylin, François Simon Revue Francophone des Laboratoires.2025; 2025(576): 16. CrossRef
A novel model for predicting the risk of liver cirrhosis in people living with HIV/HBV coinfection: a study based on proteomic analysis Rongrong Yang, Ping Xu, Xien Gui, Yongxi Zhang, Yong Xiong BMC Infectious Diseases.2025;[Epub] CrossRef
AST to ALT ratio as a prospective risk predictor for liver cirrhosis in patients with chronic HBV infection Xiaohuan Lai, Haiyan Chen, Xiaofeng Dong, Guanlin Zhou, Dong Liang, Fei Xu, Hongxia Liu, Yingmin Luo, Hui Liu, Shaogui Wan European Journal of Gastroenterology & Hepatology.2024; 36(3): 338. CrossRef
The significance of m6A RNA methylation regulators in diagnosis and subtype classification of HBV-related hepatocellular carcinoma Qijuan Zang, Yalin Ju, Siyi Liu, Shaobo Wu, Chengbin Zhu, Liangru Liu, Weicheng Xu, Yingli He Human Cell.2024; 37(3): 752. CrossRef
Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA Jian Wang, Li Zhu, Shaoqiu Zhang, Zhiyi Zhang, Tao Fan, Fei Cao, Ye Xiong, Yifan Pan, Yuanyuan Li, Chao Jiang, Shengxia Yin, Xin Tong, Yali Xiong, Juan Xia, Xiaomin Yan, Yong Liu, Xingxiang Liu, Yuxin Chen, Jie Li, Chuanwu Zhu, Chao Wu, Rui Huang Emerging Microbes & Infections.2024;[Epub] CrossRef
Two Concepts of Hepatitis B Core-Related Antigen Assay: A Highly Sensitive and Rapid Assay or an Effective Tool for Widespread Screening Takako Inoue, Shintaro Yagi, Yasuhito Tanaka Viruses.2024; 16(6): 848. CrossRef
Role of hepatitis B core‐related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta‐analysis Qi‐Hang Cao, Hui Liu, Lun‐Jie Yan, Han‐Chao Wang, Zi‐Niu Ding, Xin‐Cheng Mao, Rui‐Zhe Li, Guo‐Qiang Pan, Xiao Zhang, Bao‐Wen Tian, Cheng‐Long Han, Zhao‐Ru Dong, Si‐Yu Tan, Dong‐Xu Wang, Yu‐Chuan Yan, Tao Li Journal of Gastroenterology and Hepatology.2024; 39(8): 1464. CrossRef
Kinetics of the hepatitis B core‐related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide Norio Itokawa, Masanori Atsukawa, Akihito Tsubota, Toru Ishikawa, Hidenori Toyoda, Koichi Takaguchi, Tsunamasa Watanabe, Chikara Ogawa, Atsushi Hiraoka, Hironao Okubo, Haruki Uojima, Makoto Chuma, Akito Nozaki, Keizo Kato, Shigeru Mikami, Joji Tani, Asahi Hepatology Research.2024; 54(11): 993. CrossRef
Macrophage-2-Binding Protein Glycosylation Isomer (M2BPGi) and AGAP Score as Markers of Noninvasive Test for Liver Fibrosis versus FibroScan in Chronic Hepatitis B Patients: A Retrospective Observational Study Laila Kurnia Pramono, Anna Tjandrawati, Dewi Kartika Turbawaty, Tiene Rostini, Muhammad Begawan Bestari, Haryono, Deny Budiman, Prapanca Nugraha, Dirk Uhlmann International Journal of Hepatology.2024; 2024: 1. CrossRef
Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence‐Based Review on Emerging Clinical Data Yujing Li, Fada Wang, Jing Zhou, Lanqing Li, Chengrun Song, Enqiang Chen Clinical Pharmacology & Therapeutics.2024; 116(2): 295. CrossRef
Latest insights into the epidemiology, characteristics, and therapeutic strategies of chronic hepatitis B patients in indeterminate phase Junye Liu, Yan Yu, Heping Zhao, Lei Guo, Wenjuan Yang, Yuzhu Yan, Jing Lv European Journal of Medical Research.2024;[Epub] CrossRef
Quantitative PCR-based high-sensitivity detection of HBV-DNA levels reflects liver function deterioration in patients with hepatitis B virus-related cirrhosis Hao Zhang American Journal of Translational Research.2024; 16(6): 2301. CrossRef
Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis Dae‐Hwan Kim, Minjeong Sung, Myong‐Suk Park, Eun‐Gene Sun, Sumin Yoon, Kyung Hyun Yoo, Kamalakannan Radhakrishnan, Sung Yun Jung, Woo‐Kyun Bae, Sang‐Hee Cho, Ik‐Joo Chung Cancer Communications.2024; 44(10): 1106. CrossRef
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma Lung-Yi Mak Journal of Liver Cancer.2024; 24(2): 145. CrossRef
HBV Biomarkers and Their Role in Guiding Treatment Decisions Lung-Yi Mak, Tobias Boettler, Upkar S. Gill Seminars in Liver Disease.2024; 44(04): 474. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
A bibliometric and visualized analysis of liver fibrosis from 2002 to 2022 Qianqian Zhao, Luhua Liang, Fei Zhai, Guixia Ling, Rongwu Xiang, Xiwei Jiang Journal of Gastroenterology and Hepatology.2023; 38(3): 359. CrossRef
A critique and systematic review of the clinical utility of hepatitis B core-related antigen Celina Adraneda, Yong Chuan Tan, Ee Jin Yeo, Guan Sen Kew, Atefeh Khakpoor, Seng Gee Lim Journal of Hepatology.2023; 78(4): 731. CrossRef
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB” Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 191. CrossRef
New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block? Young-Suk Lim Clinical and Molecular Hepatology.2023; 29(1): 118. CrossRef
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2023; 29(1): 113. CrossRef
Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas Ivana Lazarevic, Ana Banko, Danijela Miljanovic, Maja Cupic Viruses.2023; 15(2): 373. CrossRef
Effects of Entecavir on Serum Hepatitis B Virus-DNA, Interferon-γ, and Pregenomic RNA in Patients with Chronic Hepatitis B Virus Infection Xuyang Gong, Zhitao Chen, Xiaoxia Zhang, Yi Zheng, Heng Zhang Hepatitis Monthly.2023;[Epub] CrossRef
Research progress on detection methods for hepatitis B virus covalently closed circular DNA Fenglan Sun, Wei Xia, Yaoling Ouyang Journal of Viral Hepatitis.2023; 30(5): 366. CrossRef
The association of serum immunoglobulin and complement levels and liver fibrosis and inflammation stage in patients with chronic hepatitis B Mingjian Lian, Qianming Wang, Shidong Chen, Yuanyuan Yang, Guolin Hong Journal of Viral Hepatitis.2023; 30(5): 437. CrossRef
Construction of a Lasso regression-based prediction model for development of cirrhosis in chronic hepatitis B Ying Li, Ke-Xing Han, Qian Su, Nan Xu, Qin-Xiu Xie, Yu-Feng Gao World Chinese Journal of Digestology.2023; 31(7): 282. CrossRef
The role of different viral biomarkers on the management of chronic hepatitis B Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2023; 29(2): 263. CrossRef
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications Qian Zhong, Xina Xiao, Yijie Qiu, Zhiqiang Xu, Chunyu Chen, Baochen Chong, Xinjun Zhao, Shan Hai, Shuangqing Li, Zhenmei An, Lunzhi Dai MedComm.2023;[Epub] CrossRef
HIV-HBV Coinfection—Current Challenges for Virologic Monitoring Simona Ruta, Laura Grecu, Diana Iacob, Costin Cernescu, Camelia Sultana Biomedicines.2023; 11(5): 1306. CrossRef
Current and novel modalities for management of chronic hepatitis B infection Iman Ibrahim Salama, Samia M Sami, Somaia I Salama, Ghada A Abdel-Latif, Fatma A Shaaban, Walaa A Fouad, Aida M Abdelmohsen, Hala M Raslan World Journal of Hepatology.2023; 15(5): 585. CrossRef
Association of genetic polymorphisms in the C19orf66 gene and biochemical indices of HBV infected individuals in Yunnan Ni Liu, Min Liu, Jun Yang, Shuwei Dong, Ming Yue, Peng Huang, Xueshan Xia, A-Mei Zhang Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
Improved on-treatment fibrosis-4 during antiviral therapy and lower hepatocellular carcinoma risk in cirrhotic patients with hepatitis B Joo Hyun Oh, Yewan Park, Myung Ji Goh, Dong Hyun Sinn, Sang Bong Ahn, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik Scientific Reports.2023;[Epub] CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study Heejoon Jang, Su Jong Yu, Hong Ghi Lee, Tae Min Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Jung-Hwan Yoon, Yoon Jun Kim Journal of Korean Medical Science.2023;[Epub] CrossRef
Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang BMC Gastroenterology.2023;[Epub] CrossRef
Value of XGBoost machine learning model for diagnosis of hepatitis B cirrhosis Ji Li, Ke-Xing Han, Jia-Pei Shen, Wei-Jie Sun, Long Gao, Yu-Feng Gao World Chinese Journal of Digestology.2023; 31(13): 544. CrossRef
The incidence of liver abnormalities is higher in inactive hepatitis B virus carriers with influenza A infection Liqin Sun, Yong‐Mei Yin, Nan Xiao, Cheng Wang, Xiao‐Guang Li, Jun Wang, Hongzhou Lu iLABMED.2023; 1(2): 93. CrossRef
Editorial: The role of novel hepatitis B biomarkers in solving therapeutic dilemmas Ivana Lazarevic, Valentina Svicher, Maja Cupic Frontiers in Medicine.2023;[Epub] CrossRef
Increased liver stiffness promotes hepatitis B progression by impairing innate immunity in CCl4-induced fibrotic HBV+ transgenic mice Grace Bybee, Youra Moeun, Weimin Wang, Kusum K. Kharbanda, Larisa Y. Poluektova, Srivatsan Kidambi, Natalia A. Osna, Murali Ganesan Frontiers in Immunology.2023;[Epub] CrossRef
Integrative analysis reveals that SLC38A1 promotes hepatocellular carcinoma development via PI3K/AKT/mTOR signaling via glutamine mediated energy metabolism Hua-guo Feng, Chuan-xin Wu, Guo-chao Zhong, Jian-ping Gong, Chun-mu Miao, Bin Xiong Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15879. CrossRef
Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet Yun-Kai Dai, Hai-Na Fan, Kai Huang, Xin Sun, Zhi-Min Zhao, Cheng-Hai Liu World Journal of Hepatology.2023; 15(9): 1043. CrossRef
Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka Clinical and Molecular Hepatology.2023; 29(4): 851. CrossRef
Serum ribonucleotide reductase M2 is a potential biomarker for diagnosing and monitoring liver fibrosis in chronic hepatitis B patients Yating Zhan, Qiqi Tao, Zhichao Lang, Lifan Lin, Xinmiao Li, Suhui Yu, Zhengping Yu, Guangyao Zhou, Kaifeng Wu, Zhenxu Zhou, Zhixian Yu, Jianjian Zheng Journal of Medical Virology.2023;[Epub] CrossRef
Interpreting Serogical Markers in Hepatitis B Virus Infection Yasmeen Ahmed, Mohamed El-Kassas Infectious Diseases in Clinical Practice.2023;[Epub] CrossRef
Current tests for diagnosis of hepatitis B virus infection and immune responses of HBV-related HCC Wanting Shi, Kang Li, Yonghong Zhang Frontiers in Oncology.2023;[Epub] CrossRef
Biomarcadores convencionales y emergentes en hepatitis B Juan Ignacio Marín-Zuluaga, Ana Isabel Toro-Montoya Hepatología.2023; 4(2): 131. CrossRef
Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim American Journal of Gastroenterology.2022; 117(2): 288. CrossRef
Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma Hira Hanif, Mukarram Jamat Ali, Ammu T Susheela, Iman Waheed Khan, Maria Alejandra Luna-Cuadros, Muzammil Muhammad Khan, Daryl Tan-Yeung Lau World Journal of Gastroenterology.2022; 28(2): 216. CrossRef
Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy Fanghua Chen, Junming Wang, Yingcheng Wu, Qiang Gao, Shu Zhang Frontiers in Oncology.2022;[Epub] CrossRef
Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis Seunghwan Shin, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Diagnostics.2022; 12(2): 441. CrossRef
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients Carlotta Cerva, Romina Salpini, Mohammad Alkhatib, Vincenzo Malagnino, Lorenzo Piermatteo, Arianna Battisti, Ada Bertoli, Jeff Gersch, Vera Holzmayer, Mary Kuhns, Gavin Cloherty, Ludovica Ferrari, Campogiani Laura, Elisabetta Teti, Maria Cantonetti, Willi Biomedicines.2022; 10(2): 443. CrossRef
Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study Young Eun Chon, Soo Young Park, Seung Up Kim, Han Pyo Hong, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Viral Hepatitis.2022; 29(4): 289. CrossRef
Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients Han Ah Lee, Hyun Woong Lee, Younhee Park, Hyon-Suk Kim, Yeon Seok Seo Journal of Clinical Medicine.2022; 11(6): 1729. CrossRef
Application of Health Education Model Based on Theory of Behavior Change in Nursing Care of Patients with Chronic Hepatitis B Ying Luo, Zhenhua Dong, Suying Qi, Weiguo Li Journal of Nanomaterials.2022;[Epub] CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Role of hepatitis B virus in development of hepatocellular carcinoma: Focus on covalently closed circular DNA Claryssa Bianca, Elizabeth Sidhartha, Claudio Tiribelli, Korri Elvanita El-Khobar, Caecilia H C Sukowati World Journal of Hepatology.2022; 14(5): 866. CrossRef
Diagnostic Value of Combined Detection via Protein Induced by Vitamin K Absence or Antagonist II, Alpha-Fetoprotein, and D-Dimer in Hepatitis B Virus-Related Hepatocellular Carcinoma Fang Peng, Hao Yuan, Yi-Feng Zhou, Si-Xian Wu, Zhen-Yi Long, Ya-Meng Peng International Journal of General Medicine.2022; Volume 15: 5763. CrossRef
Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis Yun-Kai Dai, Zhi-Min Zhao, Chenghai Liu Frontiers in Pharmacology.2022;[Epub] CrossRef
Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim Cancers.2022; 14(20): 5002. CrossRef
Risk Predictive Model Based on Three DDR-Related Genes for Predicting Prognosis, Therapeutic Sensitivity, and Tumor Microenvironment in Hepatocellular Carcinoma Renzhi Hu, Xiping Liang, Qiying Li, Yao Liu, Zhongjie Shi Journal of Oncology.2022; 2022: 1. CrossRef
Traditional Chinese medicine: An important source for discovering candidate agents against hepatic fibrosis Wen-Qing Li, Wen-Hao Liu, Die Qian, Jia Liu, Shi-Qiong Zhou, Lei Zhang, Wei Peng, Li Su, Hong Zhang Frontiers in Pharmacology.2022;[Epub] CrossRef
Correlation of Serum M-CSF, CER, and TIMP-1 Levels with Liver Fibrosis in Viral Hepatitis Hairong Yao, Xuan Yang, Man Yan, Xueqin Fang, Yange Wang, Hong Qi, Li Sun, Min Tang Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa Jeanne Perpétue Vincent, Gibril Ndow, Shintaro Ogawa, Amie Ceesay, Ramou Njie, Bakary Sanneh, Ignatius Baldeh, Umberto D’Alessandro, Maimuna Mendy, Mark Thursz, Isabelle Chemin, Yasuhito Tanaka, Maud Lemoine, Yusuke Shimakawa Journal of Global Health.2022;[Epub] CrossRef
Response to Liao et al. Byungyoon Yun, Jin-Ha Yoon, Beom Kyung Kim American Journal of Gastroenterology.2022; 117(10): 1718. CrossRef
Updated Treatment Guidelines for Chronic Hepatitis B Jihyun An The Korean Journal of Medicine.2022; 97(6): 353. CrossRef
Diagnostic accuracy of mac‐2‐binding protein glycosylation isomer for diagnosing hepatitis B‐related fibrosis: A meta‐analysis Ming Jian Lian, Zhi Qi Chen, Qian Ming Wang, Gang Sen Zheng, Guo Lin Hong Journal of Digestive Diseases.2022; 23(10): 550. CrossRef
Study of hepatitis B core-related antigen as a predictor marker of hepatocellular carcinoma in patients with chronic hepatitis B Fatma A.-Z.A. Yousri, Sarah M.A. Hamam, Dina H. Ziada, Amany M. Abo-El Enein Tanta Medical Journal.2022; 50(1): 32. CrossRef
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park Hepatology International.2021; 15(5): 1083. CrossRef
Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2021; 13(23): 5892. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
Hepatitis B Core-Related Antigen: From Virology to Clinical Application Hye Won Lee, Sang Hoon Ahn, Henry Lik-Yuen Chan Seminars in Liver Disease.2021; 41(02): 182. CrossRef
The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection Hiroyuki Amano, Tatsuo Kanda, Hitoshi Mochizuki, Yuichiro Kojima, Yoji Suzuki, Kenji Hosoda, Hiroshi Ashizawa, Yuko Miura, Shotaro Tsunoda, Yosuke Hirotsu, Hiroshi Ohyama, Naoya Kato, Mitsuhiko Moriyama, Shuntaro Obi, Masao Omata Viruses.2021; 13(11): 2216. CrossRef
Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma Si-Young Kim, Hee-Seung Lee, Seung-Min Bang, Dai-Hoon Han, Ho-Kyoung Hwang, Gi-Hong Choi, Moon-Jae Chung, Seung-Up Kim Cancers.2021; 13(8): 1828. CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
Recent Advances in Hepatitis B Treatment Georgia-Myrto Prifti, Dimitrios Moianos, Erofili Giannakopoulou, Vasiliki Pardali, John Tavis, Grigoris Zoidis Pharmaceuticals.2021; 14(5): 417. CrossRef
Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study Young Chang, Sang-Gyune Kim, Soung-Won Jeong, Jae-Young Jang, Jeong-Ju Yoo, Sae-Hwan Lee, Young-Seok Kim, Hong-Soo Kim, Hyun-Woong Lee, Suyeon Park Journal of Clinical Medicine.2021; 10(23): 5628. CrossRef
Another oral antiviral treatment, but still far away from hepatitis B virus cure Tai-Chung Tseng Clinical and Molecular Hepatology.2021; 27(2): 281. CrossRef
Mac‐2 binding protein and its glycan isomer: Where does it come from? Where is it going? Katsuya Nagaoka, Motohiko Tanaka, Yasuhito Tanaka Hepatology Research.2021; 51(10): 1026. CrossRef
Controversies in the Management of Hepatitis B Stuart K. Roberts, Ammar Majeed, William Kemp Clinics in Liver Disease.2021; 25(4): 785. CrossRef
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park Journal of Viral Hepatitis.2021; 28(11): 1570. CrossRef
Liver stiffness measured with two-dimensional shear wave elastography comparable to histopathology falls dominantly on the severe liver fibrosis Ya Li, Size Wu Clinical Hemorheology and Microcirculation.2021; 79(4): 587. CrossRef
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Viral Hepatitis.2021; 28(6): 951. CrossRef
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma Jer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng Clinical and Molecular Hepatology.2021; 27(4): 524. CrossRef
Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins Sanae Hayashi, Katsuya Nagaoka, Yasuhito Tanaka International Journal of Molecular Sciences.2021; 22(20): 11051. CrossRef
Association of the Hepatitis B Virus Large Surface Protein with Viral Infectivity and Endoplasmic Reticulum Stress-mediated Liver Carcinogenesis Wei-Ling Lin, Jui-Hsiang Hung, Wenya Huang Cells.2020; 9(9): 2052. CrossRef
A Rapid Immunochromatographic Method Based on a Secondary Antibody-Labelled Magnetic Nanoprobe for the Detection of Hepatitis B preS2 Surface Antigen Yangyang Cai, Jun Yan, Li Zhu, Hengliang Wang, Ying Lu Biosensors.2020; 10(11): 161. CrossRef
Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers Romina Salpini, Vincenzo Malagnino, Lorenzo Piermatteo, Tiziana Mulas, Mohammad Alkhatib, Rossana Scutari, Elisabetta Teti, Carlotta Cerva, Katia Yu La Rosa, Marta Brugneti, Ada Bertoli, Benedetta Rossi, Vera Holzmayer, Jeffrey Gersch, Mary Kuhns, Gavin C Microorganisms.2020; 8(11): 1819. CrossRef
First
Prev
